Infertility is the inability to conceive after a year of trying or the inability to carry a pregnancy to term. There are several treatments available to help couples overcome infertility and have a successful pregnancy. Here are some common infertility treatments:
Fertility medications: These medications can help regulate a woman’s menstrual cycle and stimulate the production of eggs. Examples include clomiphene citrate (Clomid), letrozole, and gonadotropins.
Intrauterine insemination (IUI): IUI involves placing sperm inside a woman’s uterus to facilitate fertilization. It is often used in cases of mild male factor infertility or when the woman is using donor sperm.
In vitro fertilization (IVF): IVF involves fertilizing an egg with sperm in a laboratory dish, and then transferring the resulting embryo into the woman’s uterus. It is often used in cases of infertility that cannot be treated with other methods, such as when the woman has blocked or damaged fallopian tubes or the man has a low sperm count.
Intracytoplasmic sperm injection (ICSI): ICSI involves injecting a single sperm directly into an egg to facilitate fertilization. It is often used in cases of male factor infertility or when the couple is using donor sperm.
Assisted reproductive technologies (ARTs): ARTs are a group of fertility treatments that involve the handling of eggs and sperm in the laboratory. Examples include gamete intrafallopian transfer (GIFT) and zygote intrafallopian transfer (ZIFT).
Surgeries: Certain infertility issues, such as blocked fallopian tubes or uterine abnormalities, may be treated with surgery.
Donor eggs or sperm: In some cases, couples may choose to use donor eggs or sperm to achieve pregnancy.
It is important for couples experiencing infertility to discuss their treatment options with a fertility specialist and to consider the potential risks and benefits of each option.
DISCLAIMER: The information provided in here is for general educational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for any questions you may have regarding a medical condition. Do not rely on the information provided here for decision-making or self-treatment. If you are experiencing a medical emergency, seek immediate medical attention.
Guidelines for Antenatal, Intranatal and Postnatal and New-born Management of COVID-19
The unprecedented scale of coronavirus infections or COVID-19 pandemic has affected the lives of millions of people across the globe. This has put tremendous strain on the health-care facilities and doctors, who are facing the direct brunt of this crisis and face numerous challenges in diagnosing and treating the affected people.
The central and state governments have been
actively working with medical bodies such as ICMR and health-care facilities to
formulate management guidelines for effectively tackling the growing number of
COVID-19 infections.
Some of the most vulnerable population groups in this COVID-19 pandemic are pregnant mothers, mothers who have recently delivered a child and new-born babies. The National Neonatology Forum’s (NNF) Karnataka State Chapter has taken the initiative to draft and issue the “Guidelines for Antenatal, Intranatal and Postnatal and New-born Management of COVID-19”.
The NNF Karnataka State Chapter has prepared a comprehensive and evidence-based set of guidelines for the diagnosis and management of COVID-19 during pregnancy and delivery. It has been prepared by leading and eminent Neonatologists, Gynaecologists and Obstetricians from Karnataka.
This guideline prescribing standard operating procedures (SOPs) for the management of pregnant mothers and new-borns was released on 24th July 2020. The guideline has been duly endorsed by the Honourable Chief Minister of Karnataka, Shri BS Yediyurappa, Deputy Chief Minister, Dr. Ashwath Narayan CN, Honourable Health Minister of Karnataka, Shri B. Sreeramulu and Honourable Medical Education Minister, Dr. K. Sudhakar.
Brief Background of COVID-19
Towards the end of 2019, a coronavirus was identified to be the cause of a cluster of pneumonia cases in the city of Wuhan in China. The virus rapidly reached an epidemic scale across China and subsequently throughout the world. In February 2020, the World Health Organization (WHO) designated the disease caused by the coronavirus as COVID-19.
Recent studies have reported a variation in the viral genome of the coronavirus which has improved its ability to infect human cells. It has now become the dominant strain responsible for most COVID-19 cases. Common symptoms include fever, cough, sore throat, breathing issues, headache, and abdominal pain.
The coronavirus is primarily transmitted through close-range person-to-person contact mainly via respiratory droplets from an infected individual. Other modes of transmission are airborne, fomite, faecal-oral, blood born, and mother to child. Globally there are now close to 24 million confirmed COVID-19 cases and 3.2 million cases in India alone as of August 2020.
Management of COVID-19 and Pregnancy
Pregnant women undergo physiological and immunological changes. In the case of COVID-19 infection, most pregnant women experience mild or moderate symptoms. With the existing data, there is no evidence of an increased risk of miscarriage in COVID-19 positive mothers. The risk of vertical transmission or transmission from mother to foetus is also very low. Transmission of COVID-19 from breast milk to baby is extremely rare.
Source: NNF Karnataka State Chapter: Guidelines for Antenatal, Intranatal and Postnatal and New-born Management of COVID-19, July 2020
Highlights of Guidelines for Obstetric Health Care
All pregnant women will be treated as COVID-19 suspects and all precautionary measures will be followed.
The pregnant patient will be placed in a separate ward, negative pressure will be maintained in the Operation theatres (OT), the patients will wear a triple-layer mask.
All healthcare professionals must wear Personal Protection Equipment (PPE).
The Department of health and family welfare should be immediately notified for suspected COVID-19 cases and testing should be done at Government accredited labs.
The healthcare centres must maintain a registry of confirmed COVID-19 cases.
Healthcare centres will follow universal mask policy i.e. all visitors, patients, doctors, medical and non-medical staff will wear masks.
Sanitization of diagnostic equipment such as ultrasound machines will be done after each use.
Criteria for testing for COVID-19
Under certain circumstances, the pregnant patient will be needed to undergo testing for COVID-19. The following criteria will be used to prescribe the COVID-19 test:
Symptomatic persons will travel history in the past 14 days.
Patients with severe respiratory illness.
An asymptomatic person who has had direct contact with confirmed COVID-19 case.
In addition, ICMR has announced mandatory testing of patients living in COVID-19 hotspots or containment zones even if they are asymptomatic.
Management of pregnant patients with COVID 19
Most COVID-19 positive pregnant patients exhibit only mild symptoms. Severe symptoms are observed among immunosuppressed patients and patients with chronic conditions such as diabetes, lung disease, etc. Nevertheless, apart from the general precautions, particular considerations will be given to pregnant patients with COVID-19. Some of these include:
Maintaining
high oxygen levels and keep saturations > 94%.
Conduct
radiographic investigations such as chest X-ray using abdominal shielding.
Periodic
blood analysis to monitor white blood cell count and prescribe antibiotics when
necessary.
Current
guidelines however do not recommend the use of Hydroxychloroquine or
antiviral drugs in pregnant women.
Postnatal care for mothers with COVID-19
Limited information is available on the severity of COVID-19 symptoms exhibited in new-born babies born to mothers with COVID-19. However, the risk of transmission from mother to child after birth exists. Individualized care is recommended on a case-to-case basis after a thorough risk and benefit analysis with neonatologists and the concerned families.
Breastfeeding guidelines for mothers with COVID-19
It is extremely rare for transmission of COVID-19 from mother to baby through breast milk. It is strongly recommended to initiate breastfeeding within 1 hour of birth and that the baby is exclusively breastfed for the first 6 months.
Source: NNF Karnataka State Chapter: Guidelines for Antenatal, Intranatal and Postnatal and New-born Management of COVID-19, July 2020
Mothers confirmed with COVID-19 should breastfeed the baby with facemask and practice hand hygiene.
Face-mask should be worn during all events of contact with new-born.
If the baby and mother are required to be separated temporarily, expressed breast milk is strongly recommended to be given to the new-born by a healthy caregiver.
Gloves must be worn by the caregiver when receiving bottles of expressed breast milk. After securing the cap, the bottles should be wiped with viricidal wipes and air-dried on a clean surface.
In addition, the NNF Karnataka State Chapter also provides general guidelines for Basic Hospital Management, Visitor Policy, Managing Biomedical Waste, Mental Health and Wellness support for Patients and Healthcare Professionals and District Wise Government Helpline numbers in Karnataka.
Acknowledgements: We would like to acknowledge the Dr. Prashnath and Dr. Jyothi Bandi from LittleBaby Clinic for kindly permitting us to disseminate this information for the benefit of all.
Female gamete plays a crucial role in determining embryo competence and therefore in-vitro fertilization (IVF) results. Some morphological irregularities in oocytes can be easily assessed at the light microscopy level.
Oocyte morphological assessment in the laboratory is first based on the presentation of the cumulus–corona cells. For mature oocytes, the cumulus–corona mass should appear as an expanded and mucified layer, due to active secretion of hyaluronic acid.
Following the removal of the cumulus–corona cells in preparation for intracytoplasmic sperm injection (ICSI), oocyte evaluation is more accurate and is based on the nuclear maturation status, the morphology of the cytoplasm and on polar body (PBI) is normally considered to be a marker of oocyte nuclear maturity.
An ideal mature human oocyte, based on morphological characteristics, should have a ‘normal-looking’ cytoplasm, a single polar body, an appropriate zona pellucida (ZP) thickness and proper perivitelline space (PVS). However, the majority of the oocytes retrieved after ovarian hyperstimulation exhibit one or more variations in the described ‘ideal’ morphological criteria.
Only a few morphologically detectable features of the Metaphase II oocyte indicate compromised developmental ability. Extracytoplasmic anomalies in PBI morphology, PVS size, the appearance of the ZP are simply phenotypic variations often related to in vitro culture and/or oocyte aging. On the other hand, a special deviation in the cytoplasmic texture, namely the presence of aggregations of smooth endoplasmic reticulum (SER) is potentially lethal and developmental competence of these oocytes should be interpreted with caution.
Oocyte morphology may also reflect genetic abnormalities. This is the case for giant oocytes that contain one additional set of chromosomes. These oocytes, when occurrence of giant oocytes is relatively rare after ovarian hyperstimulation, the use of these cells for IVF is dangerous.
Oocyte nuclear maturity, as assessed by light microscopy, is assumed to be at the MII stage when the PBI is visible in the PVS .
The MII stage is characterized by the alignment of the homologous chromosomes on the spindle equatorial plate during metaphase of the second meiotic division. It is generally recognized that 85% of the retrieved oocytes following ovarian hyper stimulation display the PBI and are classified as MII, whereas 10% present an intracytoplasmic nucleus called the ‘germinal vesicle’ characteristic of prophase I of the first meiotic division. Approximately 5% of the oocytes have neither a visible GV nor PBI and these oocytes are generally classified as MI oocytes. These oocytes may, however, be at the GV breakdown stage where the nuclear envelope has broken down but has not as yet progressed to true MI where the chromosomes are aligned on the metaphase plate in preparation for the completion of the first meiotic division.
Intracytoplasmic sperm injection (ICSI) is a fertility treatment that involves injecting a single sperm directly into an egg to facilitate fertilization. Here are some important things to know about ICSI:
ICSI is often used in cases of male factor infertility, when the man has a low sperm count or abnormal sperm shape or motility. It may also be used in cases of failed IVF cycles or when the couple is using donor sperm.
The ICSI process involves collecting eggs from the woman and sperm from the male partner or a sperm donor, and then fertilizing the eggs in a laboratory dish using the ICSI technique. The resulting embryos are then transferred into the woman’s uterus.
The success rate of ICSI varies, and depends on factors such as the couple’s age, the cause of infertility, and the quality of the eggs and sperm. On average, the success rate for ICSI is about 50% per cycle.
ICSI is generally considered a safe procedure, but there are some potential risks and side effects, such as bleeding, infection, and ovarian hyperstimulation syndrome (OHSS). There is also a small risk of multiple pregnancies with ICSI.
ICSI can be more expensive than other fertility treatments, and may not be covered by insurance in all cases. Couples considering ICSI should discuss their options with a fertility specialist and consider the financial implications of the treatment.
It is important for couples undergoing ICSI to have realistic expectations about the chances of success and to be prepared for the emotional and physical demands of the treatment process.
DISCLAIMER: The information provided in here is for general educational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for any questions you may have regarding a medical condition. Do not rely on the information provided here for decision-making or self-treatment. If you are experiencing a medical emergency, seek immediate medical attention.
Our ever-changing and rapidly evolving urban lifestyle is fueled by technology innovations in IT – telecom, medicine and food. These innovations have significantly improved the quality of our life in terms of superior digital connectivity and access to information, easy access to quality healthcare services and food commodities. However, our modern lifestyle and occupational activities have also put us under increased exposure to various potentially harmful chemicals such as endocrine disrupting chemicals (EDC), volatile organic compounds (VOCs), heavy metals and pesticides. Studies have shown that long-term exposure to these chemicals, exhibit disruptions in male and female fertility, in both human and animals. [1, 2]
What are VOCs?
Where do they come from?
Why does it matter?
Concentrations of most volatile organic compounds are higher in indoor air than outdoor air
Consequently, exposure of gametes and embryos to such harmful chemicals can have detrimental effects on their growth and development. The environment requirements for gametes and embryos were initially adapted from tissue culture laboratory systems [3]. Better understanding and increased commercial interest for gametes and embryos has led to the recognition of the importance of laboratory air quality as an important factor for the safety of gamete and embryos in IVF clinics.
Several studies (primarily conducted between 1990 – 1998) have shown that poor laboratory conditions in fertility clinics, particularly the air quality can result in impairment of gametes and embryo development thereby reducing the success-rates of such fertility clinics. In fact, studies of air quality in the older ART/IVF laboratory/clinic designs (1990 – 1998) have indicated high concentrations of VOCs (like toluene and iso propyl alcohol) compared to outdoor environment, especially in the incubators. [3, 4]
Most of these IVF clinics/labs had high-efficiency particulate air (HEPA) filters which can remove particulate materials of size ~ 0.3 microns. However, HEPA filters offer limited protection from VOCs. VOC concentration greater than 1 ppm is considered high and can cause direct toxicity to embryos. Embryo development occurs reasonable well at VOC levels of ~ 0.5 ppm, however chances of miscarriage is also very high in such cases. The VOC levels should ideally be zero or at least less than 0.2 ppm. [5]
Carbon activated air filtration (CODA) systems were first implemented in 1997 and provided efficient filtration of VOCs. Clinics which installed CODA systems in addition to HEPA filters reported an increase in high quality embryos, reduction in miscarriages and higher clinical pregnancies. [5]
Regulatory bodies in the European Union and Brazil have specified the air quality requirements in ART laboratories in view of the damaging effects of VOCs and other air contaminants. [6]
Due to the growing amount of evidence suggesting that air contaminants can affect IVF outcome, cleanroom specifications for particulate and microorganism contamination in IVF laboratories have been enforced by European Union laws under Directive 2006/86/EC.
– Esteves and Bento (2016), Asian Journal of Andrology
Heitmann et al (2015), reported a study wherein the mere improvement of air quality in their IVF facility by adopting CODA filters and strategic engineering designs of their lab, yielded nearly 10 % higher live births. No other changes were made to the laboratory equipment, protocols and lab personnel. [7]
Embryo implantation (32.4% versus 24.3%; P < 0.01) and live birth (39.3% versus 31.8%, P < 0.05) were significantly increased in the new facility compared with the old facility.
– Heitmann et al. (2015), Reproductive Biomedicine Online
In another study, Khoudja et al. (2012) studied the influence of the use of a novel-air purification system on IVF outcomes. Their air purification system removes airborne molecular contaminants and chemical air contaminants in addition to VOCs. The results were compared to the outcomes prior to filter change. Few performance indicators are summarized below:
Improvements observed in IVF laboratory performance indicators after changes in air handling systems [5]
It can be clearly inferred from
these studies that improvements in the air quality is fundamental for healthy
embryo development and successful implantation rates, thereby coinciding with
higher live births.
From this discussion, it is therefore imperative that fertility centers have better awareness about the importance of air quality and the factors which can contribute to air contamination inside clinics. The use of certain building materials such as vinyl, paints and fabrics can also contribute to increased VOC level in the clinic environment. New ventures in the IVF domain may unknowingly install vinyl flooring and other such materials for increased aesthetic appeal. This may inadvertently cause elevated levels of vinyl chloride (a known carcinogen) and other VOCs thereby posing a risk to all the stakeholders involved. Understanding and adherence to safety norms in IVF clinics will go a long way in ensuring high success rates of such clinics.
Acronyms
IVF – in-vitro fertilization
ART – Assisted Reproductive Technology
VOC – Volatile Organic Compound
References
[1] Rattan, S., Zhou, C., Chiang, C., Mahalingam, S., Brehm, E., & Flaws, J. A. (2017). Exposure to endocrine disruptors during adulthood: consequences for female fertility. Journal of Endocrinology, 233(3), R109-R129.
[2] Ten, J., Mendiola, J., Torres-Cantero, A. M., Moreno-Grau, J. M., Moreno-Grau, S., Roca, M., … & Bernabeu, R. (2008). Occupational and lifestyle exposures on male infertility: a mini review. The Open Reproductive Science Journal, 1(1), 16-21.
[3] Cohen, J., Gilligan, A., Esposito, W., Schimmel, T., & Dale, B. (1997). Ambient air and its potential effects on conception in vitro. Human reproduction (Oxford, England), 12(8), 1742-1749.
[4] Hall, J., Gilligan, A., Schimmel, T., Cecchi, M., & Cohen, J. (1998). The origin, effects and control of air pollution in laboratories used for human embryo culture. Human reproduction, 13(suppl_4), 146-155.
[5] Khoudja, R. Y., Xu, Y., Li, T., & Zhou, C. (2013). Better IVF outcomes following improvements in laboratory air quality. Journal of assisted reproduction and genetics, 30(1), 69-76.
[6] Esteves, S. C., & Bento, F. C. (2016). Air quality control in the ART laboratory is a major determinant of IVF success. Asian journal of andrology, 18(4), 596.
[7] Heitmann, R. J., Hill, M. J., James, A. N., Schimmel, T., Segars, J. H., Csokmay, J. M., … & Payson, M. D. (2015). Live births achieved via IVF are increased by improvements in air quality and laboratory environment. Reproductive biomedicine online, 31(3), 364-371.
Our team was at ACE 2019 held in Chennai, at the Leela Palace on 20th-21st July 2019. There were two-parallel sessions held on both days. The event was well-attended by Doctors, Clinicians, Embryologists, Medical Technologists, Manufactures etc. The SpOvum® team had a stall for 2 days (from 20th – 21st July 2019). The products highlighted on our stall were the RoboICSI® Dashboard and the RoboScope time-lapse imaging system. Stall visitors were gifted our customized SpOvum® pens!
Our team at ACE 2019, Leela Palace, Chennai
Some of the noteworthy talks of ACE 2019 were
“Unraveling the Secrets of Embryo Implantation” By Dr. Deepak Modi from NIRH, Mumbai
“Doing ART legally” by Hitesh Bhatt
“Is time lapse monitoring of embryos the future of embryo culture?” by Suresh Kattera
“Can KPIs help programs identify shifts in quality?” by Dean Morbeck
“Using artificial intelligence (AI) and time-lapse to improve human blastocyst morphology evolution” by Marcos Meseguer
There were also several interesting panel-discussions including one on “Real case scenarios in ART and management” and on “When good embryos fail…why and what next?”.
There was an engaging debate session on “Time-lapse imaging and incubation” wherein Dr.Keshav Malhotra spoke in favor of the technology and Dr. Pranay Ghose debated against it.
Interaction with Dr. Deepak Modi and Dr. Keshav Malhotra
Take home messages from ACE 2019
Views on Time-lapse imaging studies on embryos
Most clinicians/doctors were of the opinion that Time-lapse imaging of embryos, currently offered by commercially available devices, may not add much value to the existing ART procedures. One of the main hindrances, they believe, is the high cost involved in investing in a Time-lapse imaging system when it is possible for an embryologist to manually record/monitor the embryo development at various stages.
Most clinicians do not prefer being burdened with the additional amount of data obtained through Time-lapse imaging systems. Clinicians/doctors are also not particularly convinced about what additional value is delivered by Time-lapse imaging systems to an existing ART procedure especially when it is offered as an extra payable service to patients.
However, clinicians/doctors showed willingness to invest in Time-lapse embryo imaging systems, if:
It is offered at a lower cost
Some amount of automation and pre-processing of
the image-data, which will enable the embryologists to look at only
relevant/selected images
We believe this will be an advantage for us to effectively market the our own time lapse imaging system which aims at providing a cost-effective means to obtain time-lapse images of the developing embryo after IVF procedure. The TLM also has automated ability to monitor multiple embryos and there is promising scope to include image-processing and AI to the system.
Views on RoboICSI® Dashboard
There are many EHR and EMR handling systems. The RoboICSI® Dashboard features a distinct advantage wherein it offers ART related specialized data management to all the stake-holders involved in the ART procedure. The stake-holders include the Patients, the Doctors, the Clinicians, the Embryologists etc. They were particularly impressed that the Dashboard® does not require multiple entering of the same data and automated report generation.
Another important highlight was, more doctors presenting algorithms and more comfortable and pliant in handling large amounts of data.
Overall, our team had a great time at ACE 2019 and it was great opportunity to learn from other experts, connect with several doctors, clinicians, technologists and IVF service providers. We also got numerous constructive feedback on our products and many visitors also requested an early access to the RoboICSI® Dashboard.
Our team also had wonderful time trying out the local cuisine and also visited the famous Marina Beach in Chennai. After the event of ACE 2019, we bid farewell to one of our team members, Shubham who had worked with us since 2018. We wish him the best for his future endeavors.
In vitro fertilization (IVF) is a fertility treatment that involves fertilizing an egg with sperm in a laboratory dish, and then transferring the resulting embryo into the woman’s uterus. Here are some important things to know about IVF:
IVF is often used in cases of infertility that cannot be treated with other methods, such as when the woman has blocked or damaged fallopian tubes or the man has a low sperm count. It may also be used in cases of unexplained infertility or when the couple is using donor eggs or sperm.
The IVF process involves several steps, including hormone injections to stimulate the production of multiple eggs, egg retrieval, fertilization of the eggs with sperm in a laboratory dish, and embryo transfer.
The success rate of IVF varies, and depends on factors such as the couple’s age, the cause of infertility, and the quality of the embryos. On average, the success rate for IVF is about 40% per cycle for women under 35, but decreases significantly for older women.
IVF is generally considered a safe procedure, but there are some potential risks and side effects, such as ovarian hyperstimulation syndrome (OHSS), bleeding, and infection. There is also a small risk of multiple pregnancies with IVF.
IVF can be expensive, and may not be covered by insurance in all cases. Couples considering IVF should discuss their options with a fertility specialist and consider the financial implications of the treatment.
It is important for couples undergoing IVF to have realistic expectations about the chances of success and to be prepared for the emotional and physical demands of the treatment process.
DISCLAIMER: The information provided in here is for general educational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for any questions you may have regarding a medical condition. Do not rely on the information provided here for decision-making or self-treatment. If you are experiencing a medical emergency, seek immediate medical attention.
Intrauterine insemination (IUI) is a fertility treatment that involves placing sperm inside a woman’s uterus to facilitate fertilization. Here are some important things to know about IUI:
IUI is often used in cases of unexplained infertility, mild male factor infertility, or when the woman is using donor sperm.
The process involves collecting sperm from the male partner or a sperm donor, and then washing and concentrating the sperm to increase the chances of fertilization. The sperm is then placed inside the woman’s uterus using a thin, flexible tube called a catheter.
IUI is usually done in the office of a fertility clinic, and the procedure takes only a few minutes. The woman may be given medications to stimulate ovulation in order to increase the chances of success.
The success rate of IUI varies, and depends on factors such as the couple’s age, the cause of infertility, and the use of fertility medications. On average, the success rate for IUI is about 10-20% per cycle.
IUI is generally considered a low-risk procedure, but there are some potential side effects and complications, such as cramping, bleeding, and infection.
Couples considering IUI should discuss their options with a fertility specialist and weigh the potential risks and benefits of the treatment. It is also important to have realistic expectations about the chances of success.
DISCLAIMER: The information provided in here is for general educational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for any questions you may have regarding a medical condition. Do not rely on the information provided here for decision-making or self-treatment. If you are experiencing a medical emergency, seek immediate medical attention.
RoboICSI was at ACE Goa 2018 from 17th-19th August at Holiday Inn resort. We had a 3 day stall were many embryologist, clinicians, distributors, freelancers, students, manufacturers, IVF product suppliers visited to know about the technology and the working of the product. We had a live demo setup for the visitors to get a feel of it.
RoboICSI Soft Demo at the stall
There was a poster presentation by the team as well which was on ” Mechanics based characterization of oocytes using grippers” that explains about how bio-mechanical properties helps us to distinguish good and bad oocytes .
Poster presentation on ” Mechanics based characterisation of oocytes using grippers”
Dr Keshav Malhotra had presented a talk on “Automation in IVF” where he had talked about RoboICSI under Automation of ICSI on the 3rd day of the conference.
Clinics/ embryologists who were interested for a free demo of RoboICSI signed up with us at the stall to get to know more about the product.
There is a free signup for hands on training on RoboICSI at world-class Santaan-Origio Academy. To sign-up please do visit our blog post Hands on Training on RoboICSI
RoboICSI Team at the stall in ACE Goa 2018
Santosh Bhargav giving a demo at the stall to the visitors
Dr Ramnath Babu & Dr Santosh Bhargav explaining how the product works
Happy to be at ACE Goa 2018
RoboICSI Team had a wonderful stay and experience at ACE Goa conference 2018. We got to meet many embryologists, Clinicians, Companies who were ready to connect and get to know about the product even further.
If there are any enquiry regarding the product, dashboard or any other information please visit our website RoboICSI Website
